Preclinical studies have also demonstrated synergy between tazemetostat and venetoclax (Bcl2 inhibitor) against DLBCL, with phase-I trials currently in development (Scholze et al., 2020). This evidence concerns the gene BCL2 and diffuse large B-cell lymphoma.